SelectQuote (SLQT) Q2 2026 earnings review
Strong AEP Execution Overshadowed by Massive Guidance Cut
SelectQuote delivered a solid Q2 on paper, with Revenue growing 12% to $537M and Senior margins holding firm at 39%. However, the narrative collapsed with the FY26 outlook. Management slashed full-year Adjusted EBITDA guidance by ~30% at the midpoint ($95M vs. prior $135M), citing 'partner-driven headwinds'—specifically a carrier marketing cut and PBM reimbursement pressure. While the core Senior business remains efficient, the Healthcare Services growth engine has stalled on profitability, turning the stock into a 'show me' story on cash flow.
🐂 Bull Case
Despite market volatility, the Senior segment remains a cash cow. Q2 Adjusted EBITDA margins held at 39%, matching prior years, driven by a 22% increase in agent productivity. Customer recapture rates were strong during a disruptive AEP.
Recent refinancing extends maturities to 2031 and improves liquidity. Management forecasts FY26 Cash EBITDA of $60-70M, implying the business can service its debt even with reduced guidance.
🐻 Bear Case
The guidance cut exposes SelectQuote's dependency on third parties. A single national carrier cutting marketing spend and a PBM reimbursement change wiped out ~$40M of expected EBITDA. This lack of control over key revenue drivers is a major structural weakness.
Healthcare Services revenue grew 26%, but Adjusted EBITDA collapsed 62% to just $0.8M (0.3% margin). The promise of this segment providing stable, non-seasonal earnings is failing to materialize in the numbers.
⚖️ Verdict: 🔴
Bearish. While the Senior segment execution was excellent, the thesis drift in Healthcare Services and the severity of the guidance cut shatter investor confidence. The company is growing 'hollow' revenue in HCS that isn't dropping to the bottom line.
Key Themes
Guidance Slash & H2 Collapse
Management cut FY26 EBITDA guidance from $120-150M to $90-100M. Critically, H1 Actual EBITDA is ~$83M ($84.7M Q2 + -$1.7M Q1). This implies H2 EBITDA will be approx. $7-17M. Compared to H2 FY25 ($40.4M), this is a massive deceleration, signaling that the 'partner headwinds' are severely impacting the back half of the year.
Healthcare Services: Revenue Rich, Profit Poor
The Healthcare Services (HCS) segment was pitched as the diversifier to smooth seasonality. While revenue surged 26% to $230.7M, EBITDA margins evaporated to ~0% (down from 1% YoY). The segment is suffering from PBM reimbursement pressure. Until margins expand, this segment is dilutive to the company's overall quality of earnings.
Senior Agent Productivity
A bright spot in the report. Agent productivity increased 22% YoY. Marketing expense per policy decreased 4%. SelectQuote is proving it can acquire customers efficiently even in a 'disruptive' Medicare Advantage environment. This efficiency protected Senior margins despite volume pressure.
Life Segment Margin Compression
The Life segment is usually a steady contributor, but cracks appeared in Q2. Revenue grew 9%, but Adjusted EBITDA fell 25% YoY ($5.6M vs $7.4M). Margins compressed from 19% to 13%, blamed on 'marketing expense pressure.' This adds another layer of concern to the profitability picture.
Debt & Capital Structure Refi
The company successfully refinanced term debt, extending maturities to 2031. This removes near-term liquidity fears, which is critical given the reduced earnings outlook. The focus has shifted to 'Cash EBITDA' (guided $60-70M) to prove debt serviceability.
Other KPIs
Stable (+2% YoY). Medicare Advantage approved policies grew 4% to 257k. This stability is the company's lifeline while other segments struggle with profitability.
Accelerating top-line (+26% YoY), but the quality of this revenue is currently low due to zero margin contribution. Member count grew 17% YoY to 113k.
Reversing. Cash flow improved vs prior year (-$45.3M), but remains negative for the first half. The company relies on a strong H2 collection cycle, which is now at risk due to the guidance cut.
Guidance
Decelerating. Cut from prior range of $1.65B-$1.75B. The revision reflects the partner headwinds (marketing spend constraints). Implies ~9-10% YoY growth, down from the mid-teens previously expected.
Decelerating significantly. Cut from $120M-$150M. This implies a ~24% decline in earnings power at the midpoint vs prior expectations. The magnitude of this cut relative to revenue suggests high operating leverage working against them.
Stable/Positive. This metric excludes renewal commissions. Management highlights this to show operating liquidity. However, this is a non-GAAP derivative of a non-GAAP metric, so quality is lower.
Key Questions
PBM Dispute Resolution
Management cited PBM reimbursement changes as a major headwind. Is this a permanent structural change in the economics of SelectRx, or a one-time contract dispute? When will margins normalize?
Marketing Spend Volatility
A 'national carrier' curtailed marketing spend. How much visibility do you actually have into partner budgets for the remainder of the year, and is there risk other carriers follow suit in Q3/Q4?
Life Segment Margins
Life EBITDA margins compressed 600bps YoY. Is this marketing pressure transient, or has the cost of acquisition for Life policies permanently increased?